Chris Cornelison named interim Associate Vice President for Innovation and Commercialization

KENNESAW, Ga. | September 6, 2023

Kennesaw State University microbiology professor Chris Cornelison will serve as interim Associate Vice President for Innovation and Commercialization, effective September 1.

Cornelison, who for the past three years has served as Director of  Intellectual Property Development , will work closely with Vice President for Research Karin Scarpinato on a variety of Office of Research initiatives, focusing on applied research and venture creation.

Chris Cornelison headshot

“Chris has demonstrated his entrepreneurial expertise through the procurement of several externally funded grants, in addition to the support infrastructure he has built for faculty here at KSU,” Scarpinato said. “Moving forward, he will be instrumental in working to expand our industry relations and commercialization portfolio.”

Cornelison will primarily focus on growing applied research and entrepreneurship across the university, a focus that includes  Hatchbridge , a business incubator that launched earlier this year and assists local entrepreneurs in growing their businesses by offering resources such as guidance, office space and programming.

With many academic units at KSU already engaged in applied research, Cornelison aims to direct talent across both campuses to maximize the university’s impact on the region. Developing collaborations with Hatchbridge, Coles College of Business, Research Development and Strategic Initiatives, University Advancement, Career Planning and Development, and Government Relations will be crucial in the university reaching its full potential as a source for innovative solutions with market potential.

In addition to Intellectual Property Development duties, Cornelison also operates the  BioInnovation Laboratory , which currently has seven active external grants, highlighted by the lab’s work on white-nose syndrome in bats and the development of novel therapeutic interventions.

The lab is also active in  culinary mushroom cultivation , which includes technology that is licensed to MycoLogic, a startup Cornelison founded with postdoctoral researcher Kyle Gabriel that has garnered numerous awards in startup competitions. 

MycoLogic finished first this summer at the Georgia AgTech Summit, and earlier this year, the KSU-based startup was a finalist at the Ag Innovation Challenge sponsored by the American Farm Bureau Federation.

Cornelison’s entrepreneurial background will be essential in performing the duties of interim Associate Vice President for Innovation and Commercialization.

“As a founder of a startup at KSU, I have learned what it means to be a faculty entrepreneur,” Cornelison said. “I am thrilled to have the opportunity to support my colleagues in their pursuit of entrepreneurial activities that allow the world to benefit from the great research they are doing.”

Other BioInnovation Laboratory projects include the production of pigments from agricultural and industrial waste materials by using food-grade fungi as biocatalysts, a project that recently received venture development funding and was the research focus of 2023 Birla Carbon Summer Scholar Mark Sheehan.

Cornelison earned his B.S. in microbiology at the University of Georgia in 2009, and his M.S. and Ph.D. in applied and environmental microbiology at Georgia State University in 2011 and 2013, respectively.

It was at Georgia State University while working in the laboratory of Dr. Sidney A. Crow that Cornelison developed an interest in how research intersects with commercialization. 

“I was able to see how to build an applied research portfolio and learned about many of the ways in which research products reach their full potential via commercialization,” Cornelison said. “As a postdoc, I was part of an NSF I-Corps team. This further reinforced my desire to be active in driving academic innovations to market and gave me an appreciation for understanding product-market fit and the needs of customers.”

Cornelison carried those lessons into his role of Director of Intellectual Property Development, where he built KSU’s technology transfer operations from the ground floor by creating the Innovation Launch Pad to train faculty and student inventors in lean startup methodology and customer discovery, established the Innovation Seed Grant Program to support inventors in advancing their innovation during the provisional year, and created the KSU Quick Start Licensing Program to allow faculty to quickly obtain freedom to operate for commercial utilization of their innovations.

“Technology transfer at KSU is far more advanced than it was three years ago, and I am proud of the progress we have made,” Cornelison said.

— By David Roberts

Source: https://research.kennesaw.edu/roc/stories/cornelison_avp_innovation_commercialization.php

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.
December 4, 2025
Georgia Life Sciences’ CEO, Maria Thacker Goethe shares her perspective on the value of Georgia’s research universities in this month’s issue of Georgia Trend. “Georgia research institutions have felt a very significant impact from the federal rollbacks, specifically in NIH and NSF funding. Thacker Goethe’s message about the impact of research cuts is simple: Disruption shatters the foundational trust researchers have in grant continuity….” To read the full article, click here .
MORE POSTS